Please use this identifier to cite or link to this item:
https://www.arca.fiocruz.br/handle/icict/55596
Type
ArticleCopyright
Open access
Collections
- INI - Artigos de Periódicos [3645]
Metadata
Show full item record
TROPONIN IN COVID-19: TO MEASURE OR NOT TO MEASURE? INSIGHTS FROM A PROSPECTIVE COHORT STUDY
Author
Moll-Bernardes, Renata
Mattos, João D.
Schaustz, Eduardo B.
Sousa, Andréa S.
Ferreira, Juliana R.
Tortelly, Mariana B.
Pimentel, Adriana M. L.
Figueiredo, Ana Cristina B. S.
Noya-Rabelo, Marcia M.
Sales, Allan R. K .
Albuquerque, Denilson C.
Rosado-de-Castro, Paulo H.
Camargo, Gabriel C.
Souza, Olga F.
Bozza, Fernando A.
Medei, Emiliano
Luiz, Ronir R.
Mattos, João D.
Schaustz, Eduardo B.
Sousa, Andréa S.
Ferreira, Juliana R.
Tortelly, Mariana B.
Pimentel, Adriana M. L.
Figueiredo, Ana Cristina B. S.
Noya-Rabelo, Marcia M.
Sales, Allan R. K .
Albuquerque, Denilson C.
Rosado-de-Castro, Paulo H.
Camargo, Gabriel C.
Souza, Olga F.
Bozza, Fernando A.
Medei, Emiliano
Luiz, Ronir R.
Affilliation
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Copa D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Niterói D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Niterói D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Glória D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Bahia School of Medicine and Public Health. Cardiology Department. Salvador, BA, Brazil / Aliança Hospital. Cardiology Unit. Salvador, BA, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Rio de Janeiro State University. Cardiology Department. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Federal University of Rio de Janeiro. Institute for Studies in Public Health. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Copa D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Niterói D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Niterói D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Glória D'Or Hospital. Cardiology Unit. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Bahia School of Medicine and Public Health. Cardiology Department. Salvador, BA, Brazil / Aliança Hospital. Cardiology Unit. Salvador, BA, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Rio de Janeiro State University. Cardiology Department. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
Fundação Oswaldo Cruz. Instituto Nacional de Infectologia Evandro Chagas. Rio de Janeiro, RJ, Brasil / D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Federal University of Rio de Janeiro. National Center for Structural Biology and Bioimaging. Rio de Janeiro, RJ, Brazil.
D'Or Institute for Research and Education. Rio de Janeiro, RJ Brazil / Federal University of Rio de Janeiro. Institute for Studies in Public Health. Rio de Janeiro, RJ, Brazil.
Abstract
Myocardial injury (MI), defined by troponin elevation, has been associated with increased mortality and adverse outcomes in patients with coronavirus disease 2019 (COVID-19), but the role of this biomarker as a risk predictor remains unclear. Data from adult patients hospitalized with COVID-19 were recorded prospectively. A multiple logistic regression model was used to quantify associations of all variables with in-hospital mortality, including the calculation of odds ratios (ORs) and confidence intervals (CI). Troponin measurement was performed in 1476 of 4628 included patients, and MI was detected in 353 patients, with a prevalence of 23.9%; [95% CI, 21.8-26.1%]. The total in-hospital mortality rate was 10.9% [95% CI, 9.8-12.0%]. The mortality was much higher among patients with MI than among those without MI, with a prevalence of 22.7% [95% CI, 18.5-27.3%] vs. 5.5% [95% CI, 4.3-7.0%] and increased with each troponin level. After adjustment for age and comorbidities, the model revealed that the mortality risk was greater for patients with MI [OR = 2.99; 95% CI, 2.06-4.36%], and for those who did not undergo troponin measurement [OR = 2.2; 95% CI, 1.62-2.97%], compared to those without MI. Our data support the role of troponin as an important risk predictor for these patients, capable of discriminating between those with a low or increased mortality rate. In addition, our findings suggest that this biomarker has a remarkable negative predictive value in COVID-19.
Share